3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Burkitt Lymphoma
21
Leukemia, Biphenotypic, Acute
13
Leukemia, Myeloid, Acute
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia
5
Osteosarcoma
4
Myelodysplastic Syndromes
4
Leukemia, Myeloid, Accelerated Phase
4
Blast Crisis
4
Recurrence
3
Neoplasm Metastasis
3
Myeloproliferative Disorders
3
Lymphoma, Mantle-Cell
3
Lymphoma
3
Down Syndrome
3
Blastic Plasmacytoid Dendritic Cell Neoplasm
3
Rhabdoid Tumor
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Juvenile
2
Hemoglobinuria, Paroxysmal
2
Head and Neck Neoplasms
2
Anemia, Refractory, with Excess of Blasts
2
Waldenstrom Macroglobulinemia
1
Urothelial Carcinoma of the Bladder
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Tretinoin
3
Arsenic Trioxide
3
arsenous acid
1
Mitoxantrone
1
Methotrexate
1
Mercaptopurine
1
Magnetic Resonance Spectroscopy
1
Lisaftoclax
1
Idarubicin
1
Gemtuzumab
1
Gadolinium
1
Fluorodeoxyglucose F18
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Promyelocytic, Acute
×
Methotrexate
×
90 days
×
Clear all
NCT02688140
2026-05-29
TUD-APOLLO-064
Technische Universität Dresden
Phase 3
Completed
133 enrolled